Tianyan Pharmaceutical to Showcase Anti-CTLA-4 Safebody® ADG126 Poster at SITC Annual Meeting

Brief Summary

Adagene Inc. plans to present a poster on their CTLA-4 Safebody® ADG126 at the 39th SITC annual meeting.

Impact of The News

The event is situated at the company and product level within the economic and financial domain, focusing on Adagene’s Safebody® ADG126. The presentation of Safebody® ADG126 at SITC may enhance the company’s visibility and credibility in the cancer immunotherapy sector. This could potentially lead to increased interest from investors and collaborators, positively impacting Adagene’s stock performance and future funding opportunities. As a product-level event, the successful presentation and reception of Safebody® ADG126 could also influence future product development, partnerships, and market expansion strategies.